Compassionate use programme for use of MIS 416 in patients in New Zealand with secondary progressive multiple sclerosis.
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 20 May 2015
At a glance
- Drugs MIS 416 (Primary)
- Indications Multiple sclerosis
- Focus Expanded access; Therapeutic Use
- 20 May 2015 Results published in an Innate ImmunoTherapeutics media release.
- 17 Dec 2014 New trial record
- 12 Dec 2014 Seven patients have recently been added to the compassionate use group, bringing the total number of such patients to 25, according to an Innate Immunotherapeutics media release.